FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554490634> ?p ?o ?g. }

• W2554490634 abstract "Abstract Abstract 64 BCL6 represents a survival factor in DLBCL and FL since specific BCL6 inhibitors (i.e: the peptidomimetic RI-BPI and the small molecule 79-6) kill DLBCL and transformed FL (tFL) cell lines. Our group showed that BCL2 and other anti-apoptotic genes are transcriptionally repressed by BCL6 and could be reactivated upon treatment with RI-BPI or 79-6. We also showed that BCL6 and BCL2 control distinct and non-overlapping survival pathways in these lymphomas. This suggests that blocking the function of anti-apoptotic proteins might overcome any resistance that these proteins might mediate in response to BCL6 inhibition. In addition, constitutive expression of BCL2 has been observed in DLBCL and FL cases. We therefore hypothesized that targeting both BCL6 and BCL2 would eliminate two of the most potent survival mechanisms and would translate in synergistic killing of these lymphomas. In order to test this hypothesis, we examined the proteome-wide consequence of BCL6 inhibition in a DLBCL cell line (SU-DHL6) transfected with siBCL6 by phospho-protein arrays. We found that 280 unique proteins changed their abundance after siBCL6, 40 of them related to (pro and anti) apoptosis signaling (p<0.001). By means of pathway analysis bioinformatic tools, we then identified anti-apoptotic proteins with increased abundance after siBCL6 that could be therapeutically targeted. Among these druggable proteins we found BCL2, BCL-XL, MCL-1, NEDD8, PARP1 and several ubiquitin ligases. We confirmed in independent experiments that BCL6 knockdown induced mRNA (by qPCR) and protein up-regulation (by immunobloting) of these genes in 2 additional DLBCL and 2 tFL cell lines. Treatment of these siBCL6-transfected cell lines with small molecules inhibitors of BCL2 family members (ABT-737 and oblatoclax), NEDD8 activating enzyme (MLN4924), PARP (olaparib) and proteasome (bortezomib) showed increased killing compared to each treatment alone. In order to identify rational combinatorial therapies that could be potentially translated for use in clinical trials, we performed additional studies with the BCL6 inhibitor RI-BPI that is being developed for clinical use. We first analyzed the impact of RI-BPI on the apoptosome in a panel of 6 DLBCL (SU-DHL6, Ly1, Ly7, Ly3, Ly10, SU-DHL4) and 4 tFL (DoHH2, WSU-DLCL2, Granta452, SC-1) cell lines. RI-BPI induced a profile of up-regulated pro and anti-apoptotic proteins similar to siBCL6. Because ABT-737 and obatoclax are active in DLBCL cells where apoptotic BH3 activators are neutralized by BCL2 or BCL-XL and RI-BPI treatment changes the stoichiometry of pro and anti-apoptotic proteins, we determined the post-RI-BPI BH3 profiling accordingly to the amount of BIM sequestration (by co-immunoprecipitation). Accordingly, sequential treatment of DLBCL and tFL cell lines with RI-BPI and ABT-737 or obatoclax synergistically killed BCL2/BCL-XL dependent cells (but not MCL-1 dependent cells). This effect was independent of the mutational status of BCL2, MCL1, BCL6, MYC and TP53. Olaparib was not tested in combination since most cell lines were resistant to clinically achievable concentrations of this drug. Bortezomib and MLN4924 were synergistic in most cell lines when combined with RI-BPI (as determined by isobologram analysis). The synergistic killing was associated with increase in caspase 7/3 activation (by a plate-based assay) and NFkB inhibition (by p65 DNA binding assay). This effect was independent of the cell of origin classification of the cell line (i.e. ABC vs. GCB). We then tested the combination of RI-BPI with ABT-737, MLN4924 or bortezomib in Ly1 xenograft models (n=10 mice per combination). Ly1 represents a DLBCL with 3q27 and t(14,18). We found that after 10 days of treatment, each combinatorial treatment was more effective than their individual components (p=0.02, p=0.01 and p<0.01 for RI-BPI with ABT-737, MLN4924 and bortezomib, respectively; T-test, day 10). Detailed toxicity studies revealed no toxicity excess with these combinations. In sum, our work shows that pharmacologic targeting of anti-apoptotic pathways induced by inhibition of BCL6 activity successfully sensitized DLBCL and tFL cells to apoptosis. This effect was evident in cells in which the apoptosis resistant mechanism evolved as response to BCL6 inhibition and gene de-repression as well as those with constitutive overexpression of anti-apoptotic genes. Disclosures: No relevant conflicts of interest to declare." @default.
• W2554490634 created "2016-11-30" @default.
• W2554490634 creator A5019770989 @default.
• W2554490634 creator A5042106058 @default.
• W2554490634 creator A5059389744 @default.
• W2554490634 creator A5089528497 @default.
• W2554490634 creator A5089555790 @default.
• W2554490634 date "2012-11-16" @default.
• W2554490634 modified "2023-09-28" @default.
• W2554490634 title "Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)" @default.
• W2554490634 doi "https://doi.org/10.1182/blood.v120.21.64.64" @default.
• W2554490634 hasPublicationYear "2012" @default.
• W2554490634 type Work @default.
• W2554490634 sameAs 2554490634 @default.
• W2554490634 citedByCount "1" @default.
• W2554490634 countsByYear W25544906342013 @default.
• W2554490634 crossrefType "journal-article" @default.
• W2554490634 hasAuthorship W2554490634A5019770989 @default.
• W2554490634 hasAuthorship W2554490634A5042106058 @default.
• W2554490634 hasAuthorship W2554490634A5059389744 @default.
• W2554490634 hasAuthorship W2554490634A5089528497 @default.
• W2554490634 hasAuthorship W2554490634A5089555790 @default.
• W2554490634 hasConcept C153911025 @default.
• W2554490634 hasConcept C159654299 @default.
• W2554490634 hasConcept C190283241 @default.
• W2554490634 hasConcept C203014093 @default.
• W2554490634 hasConcept C2777408456 @default.
• W2554490634 hasConcept C2777537477 @default.
• W2554490634 hasConcept C2777938653 @default.
• W2554490634 hasConcept C2778453870 @default.
• W2554490634 hasConcept C2778461978 @default.
• W2554490634 hasConcept C2778559949 @default.
• W2554490634 hasConcept C2779338263 @default.
• W2554490634 hasConcept C2779675984 @default.
• W2554490634 hasConcept C31573885 @default.
• W2554490634 hasConcept C502942594 @default.
• W2554490634 hasConcept C54009773 @default.
• W2554490634 hasConcept C54355233 @default.
• W2554490634 hasConcept C81885089 @default.
• W2554490634 hasConcept C86803240 @default.
• W2554490634 hasConcept C96926380 @default.
• W2554490634 hasConceptScore W2554490634C153911025 @default.
• W2554490634 hasConceptScore W2554490634C159654299 @default.
• W2554490634 hasConceptScore W2554490634C190283241 @default.
• W2554490634 hasConceptScore W2554490634C203014093 @default.
• W2554490634 hasConceptScore W2554490634C2777408456 @default.
• W2554490634 hasConceptScore W2554490634C2777537477 @default.
• W2554490634 hasConceptScore W2554490634C2777938653 @default.
• W2554490634 hasConceptScore W2554490634C2778453870 @default.
• W2554490634 hasConceptScore W2554490634C2778461978 @default.
• W2554490634 hasConceptScore W2554490634C2778559949 @default.
• W2554490634 hasConceptScore W2554490634C2779338263 @default.
• W2554490634 hasConceptScore W2554490634C2779675984 @default.
• W2554490634 hasConceptScore W2554490634C31573885 @default.
• W2554490634 hasConceptScore W2554490634C502942594 @default.
• W2554490634 hasConceptScore W2554490634C54009773 @default.
• W2554490634 hasConceptScore W2554490634C54355233 @default.
• W2554490634 hasConceptScore W2554490634C81885089 @default.
• W2554490634 hasConceptScore W2554490634C86803240 @default.
• W2554490634 hasConceptScore W2554490634C96926380 @default.
• W2554490634 hasLocation W25544906341 @default.
• W2554490634 hasOpenAccess W2554490634 @default.
• W2554490634 hasPrimaryLocation W25544906341 @default.
• W2554490634 hasRelatedWork W161930446 @default.
• W2554490634 hasRelatedWork W1965208100 @default.
• W2554490634 hasRelatedWork W1986994398 @default.
• W2554490634 hasRelatedWork W1994635347 @default.
• W2554490634 hasRelatedWork W2008552722 @default.
• W2554490634 hasRelatedWork W2010029755 @default.
• W2554490634 hasRelatedWork W2040662045 @default.
• W2554490634 hasRelatedWork W2062402161 @default.
• W2554490634 hasRelatedWork W2067517982 @default.
• W2554490634 hasRelatedWork W2071654243 @default.
• W2554490634 hasRelatedWork W2115487618 @default.
• W2554490634 hasRelatedWork W2125054062 @default.
• W2554490634 hasRelatedWork W2406608101 @default.
• W2554490634 hasRelatedWork W2410738814 @default.
• W2554490634 hasRelatedWork W2540415762 @default.
• W2554490634 hasRelatedWork W2896514449 @default.
• W2554490634 hasRelatedWork W2901783207 @default.
• W2554490634 hasRelatedWork W2955519075 @default.
• W2554490634 hasRelatedWork W71615215 @default.
• W2554490634 hasRelatedWork W2551227159 @default.
• W2554490634 isParatext "false" @default.
• W2554490634 isRetracted "false" @default.
• W2554490634 magId "2554490634" @default.
• W2554490634 workType "article" @default.